Gyre Therapeutics 在内部股票出售和机构所有权变化的情况下看到空头股数的增加。 Gyre Therapeutics sees rise in short interest amid insider stock sales and institutional ownership changes.

Gyre治疗公司是一家生物制药公司,开发用于肝病的氢硝酮,12月的短期利息上升14.4%,达到952 300股。 Gyre Therapeutics, a biopharmaceutical company developing Hydronidone for liver disease, saw short interest rise by 14.4% in December, reaching 952,300 shares. 马尚江总统出售了2,000股,内部人现在拥有该公司19.52%的股票。 President Songjiang Ma sold 2,000 shares, and insiders now own 19.52% of the company's stock. 机构投资人拥有23.99%的股份。 Institutional investors own 23.99% of shares. 该库存于12月31日以10.95美元关闭,平均50天移动11.57美元。 The stock closed at $10.95 on December 31st, with a 50-day moving average of $11.57.